Panel of arbitrators affirms Amgen has sole rights to novel erythropoiesis stimulating protein. Johnson & Johnson claimed it had rights to NESP under a 1985 licensing agreement giving it rights to erythropoetin (Epogen/Procrit) for non-dialysis uses in the U.S. and all uses worldwide. As a result of the binding arbitration decision, Amgen can develop and market NESP worldwide for all indications
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth